Research Peptide Stack
Buy CJC-1295 + Ipamorelin for Research (USA): Stack, COA, Sourcing
Updated · 6 cited sources · ResearchChem Research Team
Short answer: ResearchChem supplies CJC-1295 + Ipamorelin as a single research-use vial at 5 mg of each peptide for $65, with every lot shipped with a lot number and a Certificate of Analysis sent on request. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone; ipamorelin is a selective ghrelin-receptor agonist. The two act on different sides of the GH axis — the published literature studies each separately — and are handled as a research stack for GH-axis studies in cell and animal models.
The CJC-1295 + Ipamorelin stack, exactly as shipped
- SKU: CJCIPA-55. Size: 5 mg CJC-1295 + 5 mg ipamorelin in one vial (10 mg combined, lyophilized).
- Price: $65 (/shop/cjc-ipa).
- Shipping: US domestic, cold-chain insulated — no customs hold.
- Compliance line on the 40×20 mm label: "RESEARCH USE ONLY · NOT FOR HUMAN USE".
- COA: the lot-specific Certificate of Analysis is sent on request — email [email protected] with the lot number from the vial.
- Storage: unopened at −20 °C; reconstitute with bacteriostatic water for in-vitro use.
CJC-1295 and ipamorelin are two different compounds in one vial, not a fused molecule. The $65 stack ships the same ratios used together in GH-axis research; the deeper mechanism primer is at CJC-1295 vs ipamorelin.
What CJC-1295 and ipamorelin are
CJC-1295 is a long-acting analog of human growth-hormone-releasing hormone (GHRH). The Jetté 2005 identification paper describes it as a tetrasubstituted hGRF(1-29)-albumin bioconjugate: a modified fragment of the first 29 amino acids of GHRH that forms a covalent bond with endogenous serum albumin via a maleimide, extending its half-life [1]. In healthy adults, a single dose produced a prolonged increase in GH and IGF-I: at week 1 post-administration, trough GH rose 7.5-fold, mean GH by 46%, and IGF-I by 45%, with the pulsatile pattern of GH secretion preserved [2][3].
Ipamorelin is a selective growth-hormone secretagogue — a small pentapeptide that acts at the ghrelin/GHS-R1a receptor. The Raun 1998 characterization paper reports it as the first truly selective GHS: it released GH in rat pituitary cell cultures and in anesthetized rats without raising corticotropin, cortisol, or prolactin, distinguishing it from earlier GHRPs [4]. A later human pharmacokinetic study in volunteers fit the GH response with a sigmoidal Emax model, consistent with a classic receptor-mediated secretagogue [5].
The numbers above are measurements from the cited peer-reviewed trials. The ResearchChem vial is supplied for in-vitro and animal research only; the paragraphs are not instructions for use.
Why the two are studied as a stack
CJC-1295 and ipamorelin act on different arms of the GH axis: CJC-1295 is a GHRH-receptor agonist that extends the GHRH side, while ipamorelin is a GHS-R1a agonist that works through the ghrelin side [1][4]. The two receptors use partially non-overlapping intracellular signaling to drive GH release, which is why combined GHRH + GHS protocols are a recurring research design in GH-axis studies. The research vial pairs the two at 5 mg each so a lab can prepare both peptides from a single lot with matching reconstitution and storage.
No regulatory agency has approved CJC-1295 or ipamorelin as a drug. Ipamorelin reached phase 2b for postoperative ileus but was not advanced to approval [6]. The material is supplied for in-vitro and animal research only.
What the COA on a CJC-1295 + Ipamorelin lot shows
| Field | What it tells you | What to check |
|---|---|---|
| Lot number | Which production run the results belong to | Matches the lot printed on the vial |
| Sequence or formula | Which molecules were tested | Both compounds named; one COA may cover both or ship as two linked COAs |
| Identity (MS) | Measured molecular mass vs theoretical mass | Observed mass matches both the CJC-1295 and the ipamorelin theoretical masses |
| Purity (HPLC) | Share of UV-absorbing material that is the main peak | A percentage for each compound plus the chromatogram |
| Methods and limits | How each result was produced and what counts as a pass | Acceptance criteria next to every result |
| Lab, date, sign-off | Who tested it and when | Lab name, analysis date, analyst or QA signature |
See how to read a peptide COA for a field-by-field walkthrough. The purity figure is covered in more detail in HPLC peptide purity explained.
US-domestic sourcing
For US-based research use, a supplier should ship from within the US, supply a lot-specific COA on request, and label every vial with the standard RUO compliance line. ResearchChem carries the stack at /shop/cjc-ipa for $65, shipped cold-chain. Every order of $50 or more also receives one 100 mg GHK-Cu research vial free (SKU GHKCU-100); see free GHK-Cu with any $50 order for the exact offer terms.
Frequently asked questions
Can I buy CJC-1295 + Ipamorelin for research use in the US?
Yes. ResearchChem supplies the stack at /shop/cjc-ipa (5 mg + 5 mg in one vial, $65), shipped from within the US. Every vial carries the RUO compliance line and the lot-specific COA is sent on request.
What is CJC-1295 as a compound?
A long-acting analog of growth-hormone-releasing hormone — a modified fragment of the first 29 amino acids of GHRH that forms a covalent bond with endogenous serum albumin via a maleimide, extending its half-life.
What is ipamorelin?
A selective growth-hormone secretagogue: a small pentapeptide that acts at the ghrelin/GHS-R1a receptor and was shown in the Raun 1998 paper to release GH without raising corticotropin, cortisol, or prolactin.
Why are the two shipped together?
The research design behind the stack pairs a GHRH-receptor agonist (CJC-1295) with a GHS-R1a agonist (ipamorelin), so a lab can run combined GHRH+GHS protocols from a single lot with matching reconstitution and storage.
Are CJC-1295 or ipamorelin approved drugs?
No. Neither is an FDA-approved drug. Ipamorelin reached phase 2b for postoperative ileus but was not advanced to approval. Both are supplied for in-vitro and animal research only.
Cited studies
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology. 146(7):3052-3058 (2005). PubMed 15817669 DOI
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. J Clin Endocrinol Metab. 91(3):799-805 (2006). PubMed 16352683 DOI
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. J Clin Endocrinol Metab. 91(12):4792-4797 (2006). PubMed 17018654 DOI
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol. 139(5):552-561 (1998). PubMed 9849822 DOI
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharm Res. 16(9):1412-1416 (1999). PubMed 10496658 DOI
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. Int J Colorectal Dis. 29(12):1527-1534 (2014). PubMed 25331030 DOI
Related compounds
- CJC-1295 + Ipamorelin — GH Peptide Stack
Keep reading
Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.